ValuEngine upgraded shares of MOTIF BIO PLC/S (NASDAQ:MTFB) from a hold rating to a buy rating in a research report released on Wednesday.

Separately, HC Wainwright set a $32.00 price target on shares of MOTIF BIO PLC/S and gave the company a buy rating in a research note on Tuesday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $19.50.

Shares of NASDAQ MTFB opened at $6.08 on Wednesday. MOTIF BIO PLC/S has a 12-month low of $5.92 and a 12-month high of $11.52.

MOTIF BIO PLC/S Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Featured Story: Put Option

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MOTIF BIO PLC/S (NASDAQ:MTFB)

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.